妊娠合并结核病的诊疗进展

Abstract
Figure/Table
References (38)
Related Citation (15)

Download: PDF (454 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis infection. Latent tuberculosis infection during pregnancy has no clinical manifestations, but may develop into active tuberculosis. Most tuberculosis patients have no typical tuberculosis poisoning symptoms, but can lead to adverse pregnancy outcomes.Failure to diagnose and treat in time will have adverse effects on mothers and children, and will reduce the quality of life of these women and their families. Improving the recognition ability of obstetrics and gynecology medical staff plays an important role in identifying whether pregnant women suffer from tuberculosis and whether further treatment is needed after the illness. This article reviews the epidemiology of tuberculosis in pregnancy in recent years, the screening, diagnosis and treatment of latent combined infection during pregnancy and active tuberculosis, and provides reference for clinical practice.

Key words： Pregnancy Tuberculosis Latent tuberculosis infection Diagnosis Treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Chunyan

Cite this article:

HUANG Chunyan. Progress in diagnosis and treatment of tuberculosis in pregnancy[J]. 中国当代医药, 2022, 29(2): 33-37.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2022/V29/I2/33

[1]	World Health Organization.Global tuberculosis report 2020[EB/OL].https：//www.who.int/publications/i/item/globaltuberculosis-report-2020.
[2]	Tsang CA，Langer AJ，Navin TR，et al.Tuberculosis Among Foreign-Born Persons Diagnosed ≥10 Years After Arrival in the United States，2010-2015[J].MMWR Morb Mortal Wkly Rep，2017，66（11）：295-298.
[3]	刘家起，姜婧，王亮.2008-2017年全国肺结核发病的时空分布特征分析[J].现代预防医学，2020，47（19）：3461-3464.
[4]	王前，李涛，杜昕，等.2015-2019年全国肺结核报告发病情况分析[J].中国防痨杂志，2021，43（2）：107-112.
[5]	刘二勇，周林，成诗明，等.结核分枝杆菌潜伏性感染及预防性治疗研究进展的系统评价[J].中国防痨杂志，2013，35（ 4）：231-239.
[6]	Sobhy S，Babiker Z，Zamora J，et al.Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period：a systematic review and meta-analysis[J].BJOG，2017，124（5）：727-733.
[9]	Turetz ML，Ma KC.Diagnosis and management of latent tuberculosis[J].Curr Opin Infect Dis，2016，29（2）：205-211.
[14]	Ormerod P.Tuberculosis in pregnancy and the puerperium[J].Thorax，2001，56（6）：494-499.
[17]	肺结核诊断WS288-2017[J].中国感染控制杂志，2018，17（7）：642-652.
[19]	Adhikari M.Tuberculosis and tuberculosis/HIV co-infection in pregnancy[J].Semin Fetal Neonatal Med，2009，14（4）：234-240.
[7]	Mathad JS，Gupta A.Tuberculosis in Pregnant and Postpartum Women：Epidemiology，Management，and Research Gaps[J].Clin Infect Dis，2012，55（11）：1532-1549.
[8]	Sterling TR，Njie G，Zenner D，et al.Guidelines for the Treatment of Latent Tuberculosis Infection：Recommendations from the National Tuberculosis Controllers Association and CDC，2020[J].MMWR Recomm Rep，2020，69（1）：1-11.
[10]	Malhamé I，Cormier M，Sugarman J，et al.Latent Tuberculosis in Pregnancy：A Systematic Review[J].PLoS One，2016，11（5）：e0154825.
[11]	American Academy of Pediatrics and American College of Obstetricians and Gynecologists.Guidelines for perinatal care [M].8thedition.Washington，DC：American Academy of Pediatrics，American College of Obstetricians and Gynecologists，2017.
[12]	Zhang H，Wang L，Li F，et al.Induration or erythema diameter not less than 5 mm as results of recombinant fusion protein ESAT6-CFP10 skin test for detecting M.tuberculosis infection[J].BMC Infect Dis，2020，20：685.
[13]	World Health Organization.Systematic screening for active tuberculosis：principles and recommendations[M].Geneva：World Health Organization Document Production Services，2017.
[15]	Getahun H，Kittikraisak W，Heilig CM，et al.Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings：individual participant data meta-analysis of observational studies[J].PLoS Med，2011，8：e1000391.
[16]	Kali PB，Gray GE，Violari A，et al.Combining PMTCT with active case finding for tuberculosis[J].J Acquir Immune Defic Syndr，2006，42（3）：379-381.
[18]	Committeeon on Obstetric Practice.Committee opinion No.723：guidelines for diagnostic imaging during pregnancy and lactation[J].Obstet Gynecol，2017，130（4）：e210-216.
[20]	Mathad JS，Gupta A.Tuberculosis in pregnant and postpartum women：epidemiology，management，and research gaps[J].Clin Infect Dis，2012，55（11）：1532-1549.
[21]	Centers for Disease Control and Prevention.Core curriculum on tuberculosis：what the clinician should know[EB/OL].https://www.cdc.gov/tb/education/corecurr/.
[22]	World Health Organization.Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance：Xpert MTB/RIF system[M].Geneva：World Health Organization，2011.
[23]	Centers for Disease Control and Prevention.Latent tuberculosis infection：a guide for primary health care providers[EB/OL].https://www.cdc.gov/tb/publications/ltbi/treatment.htm.
[24]	World Health Organization.Latent tuberculosis infection：updated and consolidated guidelines for programmatic management[M].Geneva：World Health Organization，2018.
[25]	Menzies D，Adjobimey M，Ruslami R，et al.Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults[J].N Engl J Med，2018，379（5）：440-453.
[26]	Njie GJ，Morris SB，Woodruff RY，et al.Isoniazid-rifapentine for latent tuberculosis infection：a systematic review and meta-analysis[J].Am J Prev Med，2018，55（2）：244-252.
[27]	Centers for Disease Control and Prevention.Targeted tuberculin testing and treatment of latent tuberculosis infection[J].MMWR Morb Mortal Wkly Rep，2000，49（1）：1-51.
[28]	Gupta A，Montepiedra G，Aaron L，et al.Randomised trial of safety of isoniazid preventive therapy during or after pregnancy[C].//Conference on Retroviruses and Opportunistic Infections，2018：142LB.
[29]	Moro RN，Scott NA，Vernon A，et al.Exposure to Latent Tuberculosis Treatment during Pregnancy.The PREVENT TB and the iAdhere Trials[J].Ann Am Thorac Soc，2018，15（5）：570-580.
[30]	许晓光，任祖英.PPD 试验对结核潜伏感染和预防性服药的影响[J].中国国境卫生检疫杂志，2021，44（3）：201-202.
[31]	Gupta A，Mathad JS，Abdel-Rahman，et al.Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials：Consensus Statements From an International Expert Panel[J].Clin Infect Dis，2016，62（6）：761-769.
[32]	Pillay T，Khan M，Moodley J，et al.Perinatal tuberculosis and HIV-1：considerations for resource-limited settings[J].Lancet Infect Dis，2004，4（3）：155-165.
[33]	Brittney J，Meredith B，Huang C，et al.Tuberculosis clinical presentation and treatment outcomes in pregnancy：a prospective cohort study[J].BMC Infect Dis，2020，20（1）：686.
[34]	American Academy of Pediatrics Committee on Infectious Diseases.Red book 2018-2021：report of the committee on infectious diseases[M].31stedition.Elk Grove Village，IL：American Academy of Pediatrics，2018.
[35]	World Health Organization.TB and Gender[M].Geneva：World Health Organization，2018.
[36]	World Health Organization.Tuberculosis：WHO global tuberculosis report 2014[EB/OL].http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf.
[37]	Czeizel AE，Rockenbauer M，Olsen J，et al.A populationbased case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy[J].Int J Tuberc Lung Dis，2001，5（6）：564-568.
[38]	Esmail A，Sabur NF，Okpechi I，et al.Management of drugresistant tuberculosis in special sub-populations including those with HIV co-infection，pregnancy，diabetes，organspecific dysfunction，and in the critically ill[J].J Thorac Dis，2018，10（5）：3102-3118.